ANR — Anatara Lifesciences Share Price
0.000.00%
Last trade - 00:00- AU$1.17m
- AU$0.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.87 | ||
| Price to Tang. Book | 0.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -142.57% | ||
| Return on Equity | -147.32% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 15th, 2010
- Public Since
- October 16th, 2014
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 213,383,727
- Address
- c/- Perks, Level 8, 81 Flinders Street, ADELAIDE, 5000
- Web
- https://anataralifesciences.com/
- Phone
- +61 398245454
- Contact
- David Brookes
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for ANR
Similar to ANR
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
FAQ
What is the Anatara Lifesciences share price?
As of Today at 19:14 UTC, shares in Anatara Lifesciences are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Anatara Lifesciences share price performed this year?
Shares in Anatara Lifesciences last closed at AU$0.01 and the price had moved by -88.04% over the past 365 days. In terms of relative price strength the Anatara Lifesciences share price has underperformed the ASX All Ordinaries Index by -88.54% over the past year.
What are the analyst and broker recommendations for Anatara Lifesciences?
The overall consensus recommendation for Anatara Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Anatara Lifesciences dividend yield?
Anatara Lifesciences does not currently pay a dividend.
Does Anatara Lifesciences pay a dividend?
Anatara Lifesciences does not currently pay a dividend.
When does Anatara Lifesciences next pay dividends?
Anatara Lifesciences does not currently pay a dividend.
How do I buy Anatara Lifesciences shares?
To buy shares in Anatara Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Anatara Lifesciences?
As of the previous close price of AU$0.01, shares in Anatara Lifesciences had a market capitalisation of AU$1.17m.
Where are Anatara Lifesciences shares listed?
Here are the trading details for Anatara Lifesciences:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ANR
What kind of share is Anatara Lifesciences?
Based on an overall assessment of its quality, value and momentum Anatara Lifesciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Anatara Lifesciences share price forecast for 2025?
The analyst consensus target price for shares in Anatara Lifesciences is AU$1.40. That is 25354.55% above the last closing price of AU$0.01.
Analysts covering Anatara Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Anatara Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anatara Lifesciences. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -89.81%.
As of the last closing price of AU$0.01, shares in Anatara Lifesciences were trading -87.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Anatara Lifesciences PE Ratio?
The Anatara Lifesciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Anatara Lifesciences?
Anatara Lifesciences' management team is headed by:
- Sue MacLeman - NEC
- Steve Lydeamore - CEO
- Michael West - COO
- David Brookes - NED
- Jane Ryan - NED